While these earlier-line treatments continue to be pursued in potentially less heterogeneous and aggressive prostate adenocarcinoma, additional studies are exploring combinations with other therapies, which may synergize with 177Lu-PSMA-617. This evidence concerns the gene FOLH1 and prostate adenocarcinoma.